Waiver Aids Luye’s US Approval Quest For Risperdal Consta Rival
This article was originally published in PharmAsia News
Luye has obtained a Phase III study waiver from the US FDA for its risperidone microsphere product, in a major step towards expediting the filing and potentially first US approval of a value added China-developed drug, which stands to become a rival to J&J’s Risperdal Consta.
You may also be interested in...
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.